Latency-Associated Nuclear Antigen 2 (LANA2) Antikörper

Produktnummer ABIN363228

Der Maus Monoklonal anti-Latency-Associated Nuclear Antigen 2 (LANA2) Antikörper (Klon CM-A807) (ABIN363228) detektiert spezifisch Latency-Associated Nuclear Antigen 2 (LANA2) in IF, IP, IHC, ELISA und WB. Dieser Antikörper reagiert spezifisch mit Proben aus Kaposi's sarcoma-associated herpesvirus (KSHV).

Kurzübersicht für Latency-Associated Nuclear Antigen 2 (LANA2) Antikörper (ABIN363228)

Target: Latency-Associated Nuclear Antigen 2 (LANA2)

Reaktivität: Kaposi's sarcoma-associated herpesvirus (KSHV)

Wirt: Maus

Klonalität: Monoklonal

Applikation: Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)

Klon: CM-A807

Produktdetails

Spezifität: Reacts with human and murin Kaposi's sarcoma-associated herpes virus (KSHV) ~66-70 kDa LANA2 protein and shows no cross-reactivity to cellular proteins

Aufreinigung: Purified (protein G)

Immunogen: Recombinant LANA2 fusion protein

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only :
- IHC : 1/10 to1/2000 - IF : 2 to 4 μg/mL - IP : 2 to 4 μg/mL - WB : 2 to 4 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 2 mg/mL

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Haltbarkeit: 6 months

Antigendetails

Target: Latency-Associated Nuclear Antigen 2 (LANA2)

Substanzklasse: Viral Protein

Hintergrund: LANA2 (latency-associated nuclear antigen) is an inhibitor of p53-induced transcription in reporter assays and may be an apoptosis antagonist.It is a nuclear protein associated with Kaposi's sarcoma-associated herpes virus (KSHV), or human herpes virus 8.It is found in abundance in the nuclei of cultured cells from KSHV-infected hematopoietic tissues, such as PEL (primary effusion lymphoma) and CD (multicentric Castleman's disease).It does not appear to be expressed in KS (Kaposi's sarcoma) lesions.